Conatus Pharma Q4 Loss Widens - Quick Facts

(RTTNews) - Conatus Pharmaceuticals (CNAT) posted fourth-quarter net loss applicable to common stockholders of $5.1 million, wider than $2.4 million in the comparable quarter last year. Loss per share for the latest fourth quarter was $0.33, narrower than $2.36 last year.

On average, five analysts polled by Thomson Reuters expected the company to report a loss of $0.27 per share.

Research and development expenses were $2.98 million, compared with $1.51 million last year, while general and administrative expenses were $2.12 million, up from $0.9 million in the year-ago period.